Prof. Annette Byrne

Principal Investigator

HEAD - PRECISION CANCER MEDICINE GROUP

Prof Annette Byrne is Professor (Physiology) and Head of the RCSI Precision Cancer Medicine (PCM) Group which was established in 2008 at the Royal College of Surgeons in Ireland.

In 1999, having gained a PhD in Cell Biology at the University of York, UK, Prof Byrne was awarded the John Kerner fellowship in Gynaecologic Oncology from the University of California, San Francisco. During this period she was engaged in the elucidation of novel angiogenesis targets involved in the development of ovarian cancer, as well as interrogating the in vivo activity of novel therapeutics.

Subsequently, Prof Byrne was recruited as Scientist by Pharmacyclics LLC (Sunnyvale, California) to investigate the mechanism of action of a new class of radiation/ chemotherapy under clinical development. In 2003 Prof Byrne relocated to New York where she was employed as Senior Scientist in Angion Biomedica Corp, whose main focus was developing therapeutics which manipulated angiogenesis signaling pathways. Prof Byrne returned to Ireland in 2005 to the position of Principal Investigator at University College Dublin's Conway Institute. During this engagement she was instrumental in establishing Ireland's first comprehensive Tumour Xenograft Facility and translational Pre-clinical Imaging Centre.

Prof Byrne was recruited to the Royal College of Surgeons in Ireland in 2008 as tenured Lecturer (Physiology) and Principal Investigator, RCSI Centre for Systems Medicine & Dept of Physiology and Medical Physics. Prof Byrne was promoted to Snr Lecturer in 2013 and to Associate Professor in 2017.

In 2019 Prof Byrne attained the position of full Professor.

in 2020 Prof Byrne became Director of the National Preclinical Imaging Centre (NPIC)